Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05037279
Other study ID # VRT-BCG-01
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date January 1, 2023
Est. completion date January 31, 2026

Study information

Verified date April 2022
Source Verity Pharmaceuticals Inc.
Contact Jalees Farhan
Phone 1-800-977-9778
Email medinfo@veritypharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.


Description:

This study is a randomized, active control, double-blind clinical trial aimed at demonstrating non - inferiority of VERITY-BCG to OncoTICE, the current standard of care, with respect to two-year Recurrence Free Survival (RFS) rates in NMIBC BCG - naïve patients that are at high risk for recurrence (defined as >50%). • Recurrence will be defined as the reappearance of any of the NMIBC tumors as confirmed by cystoscopic biopsy or TURBT.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 540
Est. completion date January 31, 2026
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or Female - 18 years and older - Low or high-grade NMIBC as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification and Grade 2 or 3 in the 1973 classification, diagnosed within 60 days of registration. - Pathologically confirmed and completely resected stage Ta or T1 urothelial cell carcinoma, with or without associated carcinoma in situ (CIS), diagnosed within 60 days of registration. 1. Patients with T1 disease must have imaging demonstrating no evidence of metastatic disease (based on MRI or CT scan) within 90 days of registration, to confirm stage T1N0M0 disease. 2. For patients with stage T1 disease, repeat TURBT must be performed as per standard of care/CUA guidelines. - Patients may have intermediate or high recurrence risk disease, as indicated by the probability of 2-year recurrence of = 50% based on the EORTC Bladder Cancer risk calculator. - ECOG performance status of 0-2 - Adequate organ and marrow function as defined below: - leukocytes =3,000/mcL - absolute neutrophil count =1,500/mcL - platelets =100,000/mcL - total bilirubin = 1.5 × institutional upper limit of normal (ULN) - AST(SGOT)/ALT(SGPT) =3 × institutional ULN - creatinine = institutional ULN OR glomerular filtration rate (GFR) =50 mL/min/1.73 m2 unless data exists supporting safe use of BCG at lower kidney function values, no lower than 30 mL/min/1.73 m2 - For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use contraceptive (consistent with local regulations) during 120 days after the last dose of the study treatment. Note: The use of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile-vaginal intercourse 120 days after last dose of study drug treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. - Note: A woman of non-childbearing potential is defined as follows: - Has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy); - Has had a cessation of menses for at least 12 months without an alternative medical cause, and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (refer to laboratory reference ranges for confirmatory levels). - Male patients with female partner of childbearing potential must agree to be abstinent or practice an effective method of contraception. Male patients must agree to refrain from donating sperm during the treatment period and for at least 120 days after the last dose of study treatment. Exclusion Criteria: - Presence of urothelial carcinoma involving the upper urinary tract or prostatic urethra documented by radiological imaging or biopsy, performed within 12 months of the start of treatment. Should the imaging or biopsy be performed outside the window it will be up to the physicians' discretion to re-scan/biopsy. This is considered T4 disease. - CIS only disease. - Pure squamous cell carcinoma or adenocarcinoma. - Presence of micropapillary components. - Other prior non-bladder malignancy, except for the following: - adequately treated basal cell or squamous cell skin cancer. - in situ cervical cancer. - adequately treated stage I or II cancer currently in complete remission, or any other cancer from which the patient has been disease free for five years. - patients with localized prostate cancer who are being followed by an active surveillance program are also eligible. - Prior intravesical BCG or intradermal BCG, with the exception of tuberculosis vaccination in childhood. - Chronic administration of steroids (>10 mg prednisone) at the time of randomization. - Current or planned concomitant biologic therapy, radiation therapy, hormonal therapy, chemotherapy, surgery, or other cancer therapy while on study. - Prior chemoradiation treatment (trimodal therapy or "TMT") for bladder cancer. - Currently being treated or scheduled to have treatment with any systemic or intravesical chemotherapeutic agent during the study. - Receiving any other investigational agents. - The presence of an impaired immune response irrespective of whether this impairment is congenital or caused by disease, drugs or other therapy. - Known positive HIV serology. - Presence of a urinary tract infection; treatment should be withheld until urine culture is negative and antibiotic therapy is stopped. - Trauma to the urinary bladder. In case of gross hematuria, therapy should be stopped or postponed until the hematuria has been successfully treated or has resolved. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG vaccine. - Uncontrolled intercurrent illness. - Psychiatric illness/social situations that would limit compliance with study requirements. - Pregnancy: pregnant women are excluded from this study because VERITY-BCG is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with VERITY-BCG, breastfeeding should be discontinued if the mother is treated with VERITY-BCG.

Study Design


Intervention

Drug:
Bacillus Calmette-Guerin: Strain Russian BCG-I
Induction: 80 mg weekly for 6 weeks. Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Bacillus Calmette-Guerin: Strain TICE
Induction: 50 mg weekly for 6 weeks. Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Verity Pharmaceuticals Inc.

Outcome

Type Measure Description Time frame Safety issue
Other Safety: Incidence of treatment-emergent AEs and SAEs Incidence of treatment-emergent AEs and SAEs defined according to the CTCAE v5.0; 36 months
Other Safety: Number of discontinued subjects Number of subjects discontinuing study drug due to AEs 36
Other Safety: concomitant medications Usage of concomitant medications over time. 36 months
Primary Recurrence Free Survival (RFS) at 24 months Cumulative Recurrence Free Survival (RFS) at 24 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function.
Recurrence will be defined as the reappearance of any of the NMIBC tumors as confirmed by cystoscopic biopsy or TURBT.
24 months
Secondary Recurrence Free Survival (RFS) Cumulative Recurrence Free Survival (RFS) at 36 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function. 36 months
Secondary Progression Free Survival (PFS) Progression Free Survival (PFS) at 24 months as estimated using the Kaplan - Meier estimator of the survival function. 24 months
Secondary Progression Free Survival (PFS) Progression Free Survival (PFS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function. 36 months
Secondary Overall Survival (OS) Overall Survival (OS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function. 36 months
Secondary Change in Quality of Life Change in Quality of Life as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for NMIBC (EORTC-QLQ-NMIBC24) over 36 months.
The EORTC QLQ-NMIBC24 is a 24-item self-administered questionnaire that measures health-related quality of life in patients with intermediate to high-risk NMIBC. Items are ranked by the patient from 1 to 4 indicating the extent to which they have experienced those symptoms or problems. 1 = Not at All, 2 = A little, 3=Quite a bit, 4 = Very Much.
- High Score is equivalent to more problems, except for items on sexual function and sexual enjoyment for which a high score is interpreted as better function.
36 months
Secondary Change in functioning and symptom status Change in functioning and symptom status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for Cancer Patients (EORTC-QLQ-C30) over 36 months.
The EORTC QLQ-C30 consists of 30 items and measures Health Related Quality of Life as well as presence of symptoms across all cancer types. The QLQ-C30 includes nine multi-item scales:
5 functional scales (physical, role, cognitive, emotional, and social)
3 symptom scales (fatigue, pain, and nausea and vomiting);
A global health and quality-of-life scale*
Several single-item symptom measures
28 Items are ranked 1 to 4. 1 = Not at All, 2 = A little, 3=Quite a bit, 4 = Very Much.
*2 items are ranked 1 to 7. 1=Very Poor, 7 = Excellent.
High score = More symptoms or worse problems
*High Score = Better overall health or Quality of life.
36 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A